Vivos Therapeutics VVOS
$ 2.93
1.38%
Quarterly report 2024-Q3
added 11-14-2024
Vivos Therapeutics Balance Sheet 2011-2024 | VVOS
Annual Balance Sheet Vivos Therapeutics
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
31 K | -1.11 M | -22.5 M | -16.9 M | 3.24 M | -568 K | - | - | - | - | - | - | - |
Long Term Debt |
1.2 M | 1.99 M | 298 K | 423 K | - | 525 K | - | - | - | - | - | - | - |
Long Term Debt Current |
474 K | 419 K | 1.26 M | 867 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 587 K | 1.4 M | 1.22 M | - | - | - | - | - | - | - |
Total Current Liabilities |
7.29 M | 6.81 M | 7.51 M | 7.82 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
10.3 M | 8.92 M | 8.15 M | 8.41 M | 10.5 M | 3.38 M | - | - | - | - | - | - | - |
Deferred Revenue |
2.1 M | 2.93 M | 2.4 M | 2.94 M | 2.95 M | 890 K | - | - | - | - | - | - | - |
Retained Earnings |
-93.1 M | -79.5 M | -55.6 M | -35.3 M | -23.3 M | -12.5 M | - | - | - | - | - | - | - |
Total Assets |
10.7 M | 13.7 M | 33.7 M | 25.3 M | 7.55 M | 8.2 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
1.64 M | 3.52 M | 24 M | 18.2 M | - | - | - | - | - | - | - | - | - |
Book Value |
411 K | 4.8 M | 25.5 M | 16.9 M | -2.94 M | 4.83 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
411 K | 4.8 M | 25.5 M | 16.9 M | -2.94 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Vivos Therapeutics
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.2 M | 1.2 M | 1.4 M | 1.2 M | 1.2 M | 1.2 M | - | 1.99 M | 2.4 M | 2.52 M | 1.85 M | 641 K | 1.27 M | 641 K | 106 K | 423 K | 423 K | 423 K | 423 K | 3.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
7.68 M | 9.5 M | 11.2 M | 10.3 M | 10.3 M | 11.6 M | - | 8.92 M | 8.54 M | 9.54 M | 8.7 M | 8.15 M | 8.56 M | 8.15 M | 7.61 M | 8.41 M | 8.41 M | 8.41 M | 8.41 M | 9.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.3 M | 1.8 M | 2.4 M | 2.14 M | 2.4 M | 2.4 M | - | 2.93 M | 2.4 M | 2.1 M | 2.34 M | 2.4 M | 3.7 M | 2.4 M | 2.8 M | 2.94 M | 2.94 M | 2.94 M | 2.94 M | 2.95 M | - | - | - | 890 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-101 M | -98.7 M | -96.8 M | -93.1 M | -88.8 M | -86.7 M | - | -79.5 M | -73.4 M | -67.9 M | -61.1 M | -55.6 M | -48.2 M | -55.6 M | -38.7 M | -35.3 M | -35.3 M | -35.3 M | -35.3 M | -23.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
15.3 M | 15.8 M | 11.8 M | 10.7 M | 10.3 M | 13.7 M | - | 13.7 M | 18.4 M | 24.4 M | 29.6 M | 33.7 M | 41 M | 33.7 M | 22 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 7.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
6.31 M | 6.9 M | 2.61 M | 1.64 M | 988 K | 3.94 M | 200 K | 3.52 M | 6.72 M | 12.7 M | 17.8 M | 24 M | 28.5 M | 24 M | 14.1 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 469 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
7.66 M | 6.35 M | 582 K | 411 K | 46 K | 2.11 M | - | 4.8 M | 9.86 M | 14.8 M | 20.9 M | 25.5 M | 32.5 M | 25.5 M | 14.3 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | -1.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
7.66 M | 6.35 M | 582 K | 411 K | 46 K | 2.11 M | 6.99 M | 4.8 M | 9.86 M | 14.8 M | 21 M | 25.5 M | 32.5 M | 25.5 M | 14.3 M | 25.6 M | 16.9 M | 16.9 M | 16.9 M | -2.94 M | - | - | - | 4.83 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency